Novo Nordisk unveils new drug to fight obesity, says 13% effective
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
HQ Team June 7, 2023: Ropinirole, a drug already approved for the treatment of Parkinson’s disease, has shown potential as a treatment for.